-transparent.png){kind=logo}
This article provides a review of the mutations reported so far in the lysosomal storage disease aspartylglucosaminuria (AGU). The clinical symptoms, biochemical findings, and diagnostic possibilities of the disease are introduced. The prevalence and biological consequences of the found mutations are then described, as well as the availability of a new rapid DNA test suitable for carrier screening. This test will be especially applicable in the genetically isolated Finnish population, where the carrier frequency of AGU was found to be as high as 1:36. Finally, future prospects dealing with the foreseeable therapeutic interventions of the disease are discussed.
Related Publications
E Ikonen, and
L Peltonen
January 1999,
Hereditas,
E Ikonen, and
L Peltonen
October 2006,
Journal of inherited metabolic disease,
E Ikonen, and
L Peltonen
January 1974,
Humangenetik,
E Ikonen, and
L Peltonen
October 1998,
Gene therapy,
E Ikonen, and
L Peltonen
March 2018,
Biochimica et biophysica acta. Molecular basis of disease,
E Ikonen, and
L Peltonen
September 1999,
Experimental hematology,
E Ikonen, and
L Peltonen
August 2018,
FEBS letters,
E Ikonen, and
L Peltonen
April 2001,
Human molecular genetics,
E Ikonen, and
L Peltonen
August 1991,
FEBS letters,
E Ikonen, and
L Peltonen
July 1990,
Human genetics,
